Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M.
Evans DG, et al. Among authors: welling db.
Clin Cancer Res. 2009 Aug 15;15(16):5032-5039. doi: 10.1158/1078-0432.CCR-08-3011. Epub 2009 Aug 11.
Clin Cancer Res. 2009.
PMID: 19671848
Free PMC article.
Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. CONCLUSIONS: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the populati …
Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. CONCLU …